Raymond James & Associates Igm Biosciences, Inc. Transaction History

Raymond James & Associates

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$13.74 - $25.76 $16,048 - $30,087	-1,168 Reduced 2.75%	41,348 $568,000
Q4 2022 Feb 08, 2023	BUY	$15.45 - $26.02 $29,092 - $48,995	1,883 Added 4.63%	42,516 $723,000
Q3 2022 Oct 25, 2022	BUY	$15.42 - $27.01 $29,298 - $51,319	1,900 Added 4.91%	40,633 $924,000
Q2 2022 Aug 12, 2022	SELL	$13.27 - $25.5 $17,702 - $34,017	-1,334 Reduced 3.33%	38,733 $698,000
Q1 2022 May 11, 2022	BUY	$13.42 - $29.73 $255,879 - $566,861	19,067 Added 90.8%	40,067 $1.07 Million
Q4 2021 Feb 08, 2022	BUY	$27.59 - $66.39 $14,705 - $35,385	533 Added 2.6%	21,000 $616,000
Q3 2021 Nov 02, 2021	BUY	$65.76 - $90.65 $2,564 - $3,535	39 Added 0.19%	20,467 $1.35 Million
Q2 2021 Aug 11, 2021	BUY	$57.98 - $96.6 $2,899 - $4,830	50 Added 0.25%	20,428 $1.7 Million
Q1 2021 May 14, 2021	SELL	$71.56 - $121.23 $23,972 - $40,612	-335 Reduced 1.62%	20,378 $1.56 Million
Q4 2020 Feb 12, 2021	SELL	$47.41 - $115.03 $490,171 - $1.19 Million	-10,339 Reduced 33.3%	20,713 $1.83 Million
Q3 2020 Nov 04, 2020	SELL	$43.0 - $84.01 $10,750 - $21,002	-250 Reduced 0.8%	31,052 $2.29 Million
Q1 2020 Apr 21, 2020	SELL	$31.51 - $73.75 $41,089 - $96,170	-1,304 Reduced 4.0%	31,302 $1.76 Million
Q4 2019 Feb 12, 2020	BUY	$17.25 - $49.51 $562,453 - $1.61 Million	32,606 New	32,606 $1.24 Million

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.